Pros and Cons of Merrimack Pharmaceuticals Inc. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Merrimack Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Merrimack Pharmaceuticals Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | 2.910% | -12.617% | 12.153% | 87.355% | 28.685% | 32.821% | - |
| Evolus Inc | -1.690% | -4.918% | 4.505% | 26.087% | 28.177% | 71.852% | - |
| Salarius Pharmaceuticals Inc. | -2.300% | -0.469% | 3.922% | -61.802% | -23.604% | -98.261% | -99.992% |
Comments
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for MACK provided by MarketBeat
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for MACK provided by MarketBeat
